Synthonics, Inc. is a privately-held specialty pharmaceutical company focused on the discovery and development of patentable drugs that incorporate our proprietary metal coordination chemistry. We bind metals to known pharmaceutical agents to create new products that are better absorbed and delivered and have greater therapeutic benefits than their predecessors. We patent drugs incorporating our chemistry as new compositions of matter.

Our products under development are designed to deliver best in class treatment for conditions such as Parkinson’s disease and hypothyroidism.

We are headquartered in the Virginia Tech Corporate Research Center in Blacksburg, Virginia.


We are committed to the discovery, development and commercialization of a new generation of safer and more effective pharmaceuticals. We believe that metal coordination can produce new products that deliver consistent, tangible, and discernible improvements in health and quality of life and that the successful pursuit of our mission will reward patient, investors and partners alike.